Protease-activatable cell-penetrating peptide possessing ROS-triggered phase transition for enhanced cancer therapy

Yoo, Jisang; Rejinold, N. Sanoj; Lee, DaeYong; Jon, Sangyong; Kim, Yeu‐Chun

doi:10.1016/j.jconrel.2017.08.026

Cited by 90 publications

(89 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liposomes [139][140][141][142][143][144][145] Quantum dots (QDs) [157] Polymersomes [158] Magnetic nanoparticles [159] Micelles [146][147][148][149][150][151][152][153][154][155][156] [ 160,161] External Light Liposomes [163] MSN [164] Micelles [168] [ 63,[165][166][167]169]…”

Section: Glutathione (Gsh) (4-80 µM) Disulfidementioning

confidence: 99%

DePEGylation strategies to increase cancer nanomedicine efficacy

2019

View full text Add to dashboard Cite

show abstract

Section: Glutathione (Gsh) (4-80 µM) Disulfidementioning

confidence: 99%

DePEGylation strategies to increase cancer nanomedicine efficacy

2019

View full text Add to dashboard Cite

show abstract

“…The destruction of the micelle structures was determined with DLS and two peaks containing a large aggregated form were observed, indicating the high sensitivity of the micellar system to ROS. The underlying mechanism was that thioether groups in methionine segments were changed to hydrophilic sulfoxide groups by ROS and then were induced the disassembly of micelle [20,29] . In this work, the preparation and drug release behavior of PPT/D(DMA)@DOX was used illustrated in Figure 2a.…”

Section: Resultsmentioning

confidence: 99%

“…Secondly, TOS, an analogue of vitamin E, rapidly generates ROS in cells after interacting with mitochondrial respiratory complex II and interfering the electron transportation chain in mitochondria [13] . Thioether groups in polymethionine segments are changed to hydrophilic sulfoxide groups in cancer cells due to an inundation of ROS [11,12,20] . We hypothesized that ROS concentration under pathological conditions can induce the less decomposition of the polymeric drug by the phase transitions and then exposed TOS segment interacted with mitochondria in tumor cells to generate additional ROS.…”

Section: Introductionmentioning

confidence: 99%

Dual-responsive doxorubicin-loaded nanomicelles for enhanced cancer therapy

Zhang

Zhu

Miao

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The enhancement of tumor retention and cellular uptake of drugs are important factors in maximizing anticancer therapy and minimizing side effects of encapsulated drugs. Herein, a delivery nanoplatform, armed with a pH-triggered charge-reversal capability and self-amplifiable reactive oxygen species (ROS)-induced drug release, is constructed by encapsulating doxorubicin (DOX) in pH/ROS-responsive polymeric micelle. Results: The surface charge of this system was converted from negative to positive from pH 7.4 to pH 6.8, which facilitated the cellular uptake. In addition, methionine-based system was dissociated in a ROS-rich and acidic intracellular environment, resulting in the release of DOX and α-tocopheryl succinate (TOS). Then, the exposed TOS segments further induced the generation of ROS, leading to self-amplifiable disassembly of the micelles and drug release. Conclusions: We confirms efficient DOX delivery into cancer cells, upregulation of tumoral ROS level and induction of the apoptotic capability in vitro . The system exhibits outstanding tumor inhibition capability in vivo , indicating that dual stimuli nano-system has great potential to function as an anticancer drug delivery platform.

show abstract

“…89 Cancer The findings of this study suggesting that dual-stimuli-based delivery systems have great potential in cancer therapy. 90 Although MMP-based ACPPs are known to target tumors effectively in vivo, ACPP substrates are not perfectly selective for MMPs, and MMP is not exclusively expressed in tumors. Therefore, in order to improve the targeting potential of ACPPs, Whitney et al explored other classes of proteases and substrates that might offer better specificity and flexibility than MMP-based approaches by using phage display.…”

Section: Enzyme-activated Cppsmentioning

confidence: 99%

Tumor-targeting delivery of herb-based drugs with cell-penetrating/tumor-targeting peptide-modified nanocarriers

Kebebe¹,

Liu²,

Wu³

et al. 2018

IJN

View full text Add to dashboard Cite

Cancer has become one of the leading causes of mortality globally. The major challenges of conventional cancer therapy are the failure of most chemotherapeutic agents to accumulate selectively in tumor cells and their severe systemic side effects. In the past three decades, a number of drug delivery approaches have been discovered to overwhelm the obstacles. Among these, nanocarriers have gained much attention for their excellent and efficient drug delivery systems to improve specific tissue/organ/cell targeting. In order to enhance targeting efficiency further and reduce limitations of nanocarriers, nanoparticle surfaces are functionalized with different ligands. Several kinds of ligand-modified nanomedicines have been reported. Cell-penetrating peptides (CPPs) are promising ligands, attracting the attention of researchers due to their efficiency to transport bioactive molecules intracellularly. However, their lack of specificity and in vivo degradation led to the development of newer types of CPP. Currently, activable CPP and tumor-targeting peptide (TTP)-modified nanocarriers have shown dramatically superior cellular specific uptake, cytotoxicity, and tumor growth inhibition. In this review, we discuss recent advances in tumor-targeting strategies using CPPs and their limitations in tumor delivery systems. Special emphasis is given to activable CPPs and TTPs. Finally, we address the application of CPPs and/or TTPs in the delivery of plant-derived chemotherapeutic agents.

show abstract

Protease-activatable cell-penetrating peptide possessing ROS-triggered phase transition for enhanced cancer therapy

Cited by 90 publications

References 38 publications

DePEGylation strategies to increase cancer nanomedicine efficacy

DePEGylation strategies to increase cancer nanomedicine efficacy

Dual-responsive doxorubicin-loaded nanomicelles for enhanced cancer therapy

Tumor-targeting delivery of herb-based drugs with cell-penetrating/tumor-targeting peptide-modified nanocarriers

Contact Info

Product

Resources

About